Concepedia

Peter Rueegg

PR

Statistics

Publications

10

Citations

372

H-Index

10

Active since

2000

Affiliations

Novartis (Switzerland)(Current)

Peter Rueegg is an author at Novartis (Switzerland) specializing in medicine, gastroenterology, and digestive system diseases.

Top concepts

Publications per year

2000–2011

10

Publications

10

Tegaserod, a 5‐HT<sub>4</sub> receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects

Benoît Coffin, Jean-Pierre Farmachidi, Peter Rueegg et al. · Alimentary Pharmacology & Therapeutics · 2003 · 126 citations

Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD

H. Worth, Kian Fan Chung, James M. Felser et al. · Respiratory Medicine · 2011 · 72 citations · Full text

, , +7

Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation

S. Müller‐Lissner, Gerald Holtmann, Peter Rueegg et al. · Alimentary Pharmacology & Therapeutics · 2004 · 41 citations · Full text

Tegaserod, a 5-HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS)

Stefan Mueller‐Lissner, I. Fumagalli, Karna D. Bardban et al. · Gastroenterology · 2000 · 32 citations

, , +4

Tegaserod has a favorable safety &amp; tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome (IBS)

Peter J. Whorwell, S Krumholz, Stefan Mueller Lissner et al. · Gastroenterology · 2000 · 27 citations · Full text

, , +8

1–5 of 10